ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,222.68
0.16%
Dow Jones
39,512.84
0.32%
US Dollar vs MXN
16.7804
0.00%
Brent Oil
82.585
0.00%
Bitcoin
60,819.05
0.03%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Innoviva Inc (INVA)

  7. Innoviva Inc (INVA) Noticias

INVA

Innoviva (INVA)

Innoviva Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:INVA
FechaHoraFuenteTítuloSímboloCompañía
08/05/202415:46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INVAInnoviva Inc
08/05/202415:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVAInnoviva Inc
08/05/202415:05Business WireInnoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
08/05/202406:00Business WireInnoviva to Participate in the BofA Securities Health Care ConferenceNASDAQ:INVAInnoviva Inc
24/04/202406:00Business WireInnoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024NASDAQ:INVAInnoviva Inc
07/03/202418:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
29/02/202416:01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:INVAInnoviva Inc
29/02/202415:05Business WireInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
14/02/202406:23Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:INVAInnoviva Inc
10/01/202419:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:INVAInnoviva Inc
01/11/202315:15Business WireInnoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
01/11/202315:05Business WirePositive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated GonorrheaNASDAQ:INVAInnoviva Inc
19/09/202307:30Business WireInnoviva to Participate in the Cantor Global Healthcare ConferenceNASDAQ:INVAInnoviva Inc
18/09/202307:00Business WireXACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in AdultsNASDAQ:INVAInnoviva Inc
25/08/202315:52Business WireInnoviva Appoints Stephen Basso as Chief Financial OfficerNASDAQ:INVAInnoviva Inc
02/08/202315:05Business WireInnoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
21/06/202305:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INVAInnoviva Inc
06/06/202315:05Business WireInnoviva to Participate in the Goldman Sachs Annual Global Healthcare ConferenceNASDAQ:INVAInnoviva Inc
24/05/202305:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INVAInnoviva Inc
23/05/202318:10Dow Jones NewsFDA Approves Innoviva's Bacterial Pneumonia TreatmentNASDAQ:INVAInnoviva Inc
23/05/202317:42Business WireInnoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous UseNASDAQ:INVAInnoviva Inc
17/05/202316:19Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:INVAInnoviva Inc
15/05/202316:19Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:INVAInnoviva Inc
11/05/202317:45Business WireResults from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious DiseasesNASDAQ:INVAInnoviva Inc
09/05/202316:06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:INVAInnoviva Inc
09/05/202315:32Business WireInnoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:INVAInnoviva Inc
28/04/202316:30Business WireInnoviva Announces Retirement of Board ChairmanNASDAQ:INVAInnoviva Inc
28/04/202316:05Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:INVAInnoviva Inc
28/04/202316:05Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:INVAInnoviva Inc
17/04/202315:31Business WireSulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory CommitteeNASDAQ:INVAInnoviva Inc
 Showing the most relevant articles for your search:NASDAQ:INVA

Su Consulta Reciente

CCOM
US500
US 500
NASDAQ
NVDA
NVIDIA
USOTC
BNPQY
BNP Paribas (QX)
CCOM
SILVER
SILVER
NYSE
NKE
Nike
AMEX
SPY
SPDR S&P 500
NYSE
AXP
American Express
FX
EURUSD
Euro vs US Dollar
SPI
SP500
S&P 500
NASDAQ
TSLA
Tesla
NYSE
CVX
Chevron
NYSE
MRK
Merck
NYSE
MCD
McDonalds
PM
XAUUSD
Gold vs US Dollar
FX
USDMXN
US Dollar vs MXN
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados